Aktis Oncology

Aktis Oncology company information, Employees & Contact Information

Explore related pages

Aktis Oncology email format Aktis Oncology management contacts

Related company profiles:

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

Company Details

Employees
79
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
http://www.aktisoncology.com
Keywords
guiding Aktis as we continue to advance our mission of developing innovative targeted radiopharmaceuticals for patients with unmet needs..
Competitors
Seaport Therapeutics, AvenCell, A2 Biotherapeutics, Inc., Terray Therapeutics, atbtherapeutics, Kailera Therapeutics, Aspect Biosystems, Atalanta Therapeutics, City Therapeutics, Triveni Bio.
Looking for a particular Aktis Oncology employee's phone or email?

Aktis Oncology Questions

News

Aktis Oncology to Participate in Upcoming September Investor Conferences - Lelezard

Aktis Oncology to Participate in Upcoming September Investor Conferences Lelezard

Aktis Oncology Appoints Mike Sherman To Board - citybiz

Aktis Oncology Appoints Mike Sherman To Board citybiz

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES - PR Newswire

AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES PR Newswire

Aktis Oncology raises $175m to advance radiopharmaceutical pipeline - Pharmaceutical Technology

Aktis Oncology raises $175m to advance radiopharmaceutical pipeline Pharmaceutical Technology

Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal - Fierce Biotech

Eli Lilly pays Aktis $60M upfront to further dial into radiopharma signal Fierce Biotech

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology - BioSpace

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology BioSpace

Boston radiopharmaceuticals startup inks deal worth up to $1.16B with Lilly - The Business Journals

Boston radiopharmaceuticals startup inks deal worth up to $1.16B with Lilly The Business Journals

Radiopharmaceutical firm Aktis Oncology raises $175M in Series B financing - Radiology Business

Radiopharmaceutical firm Aktis Oncology raises $175M in Series B financing Radiology Business

Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors - PR Newswire

Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors PR Newswire

Aktis Oncology Appoints Ken Herrmann, MD, MBA to its Board of Directors - citybiz

Aktis Oncology Appoints Ken Herrmann, MD, MBA to its Board of Directors citybiz

Biotech backed by Eli Lilly, Merck raises $175 million - The Business Journals

Biotech backed by Eli Lilly, Merck raises $175 million The Business Journals

Radiopharma biotech Aktis sees Big Pharma backers return for $175M series B - Fierce Biotech

Radiopharma biotech Aktis sees Big Pharma backers return for $175M series B Fierce Biotech

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE - PR Newswire

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE PR Newswire

AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS - PR Newswire

AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS PR Newswire

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS - PR Newswire

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS PR Newswire

AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST CLINICAL DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM O - PR Newswire

AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST CLINICAL DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM O PR Newswire

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors - PR Newswire

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors PR Newswire

Lilly makes another radiopharma move in collaboration with Aktis Oncology - Endpoints News

Lilly makes another radiopharma move in collaboration with Aktis Oncology Endpoints News

Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors - Pulse 2.0

Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors Pulse 2.0

Aktis Oncology - The Pharma Letter

Aktis Oncology The Pharma Letter

Aktis makes waves with $84M extension as 3 big pharmas channel funds to radiopharmaceutical pipeline - Fierce Biotech

Aktis makes waves with $84M extension as 3 big pharmas channel funds to radiopharmaceutical pipeline Fierce Biotech

Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals - geneonline.com

Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals geneonline.com

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225) - Imaging Technology News

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225) Imaging Technology News

Aktis Oncology enters radiopharmaceuticals fray with $72M series A round - BioWorld MedTech

Aktis Oncology enters radiopharmaceuticals fray with $72M series A round BioWorld MedTech

Aktis bags $72M in Novartis, BMS-backed series A to unlock power of radiopharmaceuticals - Fierce Biotech

Aktis bags $72M in Novartis, BMS-backed series A to unlock power of radiopharmaceuticals Fierce Biotech

Companies like Aktis Oncology

City Therapeutics logo - Similar company to Aktis Oncology

City Therapeutics

59
Terray Therapeutics logo - Similar company to Aktis Oncology

Terray Therapeutics

128
Aspect Biosystems logo - Similar company to Aktis Oncology

Aspect Biosystems

119
A2 Biotherapeutics, Inc. logo - Similar company to Aktis Oncology

A2 Biotherapeutics, ...

123
Kailera Therapeutics logo - Similar company to Aktis Oncology

Kailera Therapeutics

121
Atalanta Therapeutics logo - Similar company to Aktis Oncology

Atalanta Therapeutics

61
AvenCell logo - Similar company to Aktis Oncology

Avencell

71
atbtherapeutics logo - Similar company to Aktis Oncology

Atbtherapeutics

28
Seaport Therapeutics logo - Similar company to Aktis Oncology

Seaport Therapeutics

55
Triveni Bio logo - Similar company to Aktis Oncology

Triveni Bio

41

Top Aktis Oncology Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant